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Abstract
Progressive multifocal leukoencephalopathy (PML) is a viral infection predominantly seen in patients with HIV infection. However,
with the increased use of monoclonal antibodies (MAB) for various lymphoproliferative disorders, we are now seeing this
infection in non-HIV patients on drugs such as natalizumab, rituximab, and so on. The aim of this article is to review the relationship between the occurrence of PML and MAB used in the treatment of hematological malignancies and autoimmune diseases.
Review of articles from PubMed-indexed journals which study PML in relation to the use of MAB. Relevant literature demonstrated an increased risk of reactivation of latent John Cunningham polyomavirus (JCV) resulting in development of PML in
patients on long-term therapy with MAB. The highest incidence of 1 PML case per 1000 treated patients and 1 case per 32 000 was
observed in patients treated with natalizumab and rituximab, respectively. Serological and polymerase chain reaction tests for the
detection of JCV can be helpful in risk stratification of patients for the development of PML before and during therapy with MAB.
Treatment with MAB can result in development of PML. Clinicians should include PML in differential diagnosis in patients treated
with these agents if they manifest central nervous system symptoms.
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Introduction
Progressive multifocal leukoencephalopathy (PML) was first
described in 1958 by Astrom et al.1 In 1965, ZuRhein and Chou
suggested that a papovavirus was the cause of PML.2 In the
largest review of PML to that date published in 1984, Brooks
and Walker identified 230 cases that were published in the
English-written literature or from their own experience.3 Of
these, 69 patients were pathologically confirmed and only 40
tested positive with viral tests and pathology.3 Ninety-five percent of patients had an underlying condition that predisposed
them to PML, of which nearly two-thirds had an underlying
B-cell lymphoproliferative disorder (LPD) while an underlying
primary immunodeficiency was evident in 16% of cases.4-6
With the concern of association of PML and B-cell LPD, the
risk of developing PML in patients on therapies that alter the
B-cell function became an important issue. As the use of
monoclonal antibodies (MAB) such as natalizumab, rituximab,

and efalizumab increased, there was also a rise in the literature
of PML cases in patients treated with these antibodies. Due to a
life-threatening clinical course of PML, it is important for clinicians to gain a better understanding of the pathogenesis of the
John Cunningham polyomavirus (JCV), risk of JCV reactivation, and how different anti-CD20-directed MAB may play a
role in this reactivation. This review aims to educate clinicians
on these issues.
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A search of PubMed-indexed journals was used to find articles related to JCV, PML, and MAB. The search was limited to
the last 20 years to get the most recent information on these
agents and risk of developing PML.

The JCV
The JCV is a DNA virus of the human polyomavirus family.2
Serum antibodies to JCV are found in 50% to 70% of the healthy
general population, indicating that JCV is ubiquitous in humans.
The JCV encodes the large T antigen (TAg), small T antigen, 3
virus capsid proteins, and an agnoprotein in its genome. The
JCV-encoded TAg plays an important role in virus replication
by binding to the viral origin of replication through a DNAbinding domain. The nuclear localization signal in TAg recruits
TAg to the nucleus, and the helicase domain in TAg unwinds the
DNA double helix and promotes viral DNA replication.7
The passage of the JCV through the body can be stratified
into several steps including primary viremia, latency, and reactivation. Two portals of entry for JCV into the body have been
suggested: the tonsils and the gastrointestinal tract.7,8 Primary
viremia is usually asymptomatic and occurs in childhood. After
primary infection, the virus remains in the body in a latent state
in the kidneys, tonsils, bone marrow, spleen, brain, lymph
nodes, and lungs.7,8 Reactivation can occur following immunosuppression or after elimination of the B cells with drugs
targeting B cells such as rituximab.
It has been suggested that after the initial infection the virus
transforms into a neurotropic form by gene rearrangement and
replicates in glial tissues. B cells have the capacity to harbor
JCV with diverse regulatory regions, including neurotropic
JCV.7,9,10 The gene rearrangement in the noncoding control
region of the neurotropic JCV permits binding to the NF-1X
binding protein that glial cells share with B cells.11-14 Therefore, B cells are the logical, though not proven, site of the
mutation as they have a unique genetic machinery that facilitates gene rearrangements through the addition and deletion of
nucleotides and somatic hypermutation. The cellular immune
response is most important in preventing and controlling
JCV.15-16 There is no evidence that the presence of antibody
offers any protection from future infection. On the other hand,
the importance of cell-mediated immunity is indicated by the
correlation between an impaired Th1-type T helper function
and clinical manifestation of PML.16 The significant role of
cytotoxic T lymphocytes directed against JCV in controlling
the disease has been established.17,18 Given the large number of
individuals in general population infected with JCV, rarity of
PML indicates that substantial barriers to its development must
exist in immunocompetent individuals.

Diagnosis of PML
Progressive multifocal leukoencephalopathy is suspected in
patients who have subcortical white matter lesions. Berger
et al19 found that hemiparesis, visual impairment, and altered
mentation were the 3 most common initial manifestations as well
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as the most frequent signs during the course of AIDS-related
PML. A small number of patients present with signs and symptoms referable to the posterior fossa, that is, ataxia, dysmetria,
and dysarthria, which is usually indicative of involvement of the
cerebellum and brain stem.20,21 Other signs and symptoms associated with PML include headache, vertigo, seizures, sensory
deficits, parkinsonism, aphasia, and neglect syndromes.3,19
Progressive multifocal leukoencephalopathy has been identified in association with conditions affecting the immune system. The most common diseases associated with PML are HIV,
hematological malignancies, and MAB treatment. In the setting
of hematological malignancies, a population-based study estimated the PML incidence at 0.07%.22 These results were based
on only 3 cases of PML identified over a period of 11 years in a
single Canadian province.23 Accurate calculation of the risk of
PML attributable to the underlying malignancy as opposed to
treatment-related immunosuppression is complicated by a rarity of this disease and a few larger clinical. Among the MAB
that increase the risk of PML, the most common are natalizumab, an a4b7 integrin antagonist, and rituximab.
Table 1 summarizes clinical and pathological features of
PML. When PML is suspected, neurological examination is
the first important step followed by both laboratory testing and
imaging. Brain magnetic resonance imaging shows characteristic findings of subcortical lesions. Electroencephalogram can
show focal slowing of brain waves but is nonspecific. Cerebrospinal fluid (CSF) can reveal elevation of protein and an
increased cell count. The JCV polymerase chain reaction
(PCR) test can be done on CSF, which can confirm a diagnosis.
Brain biopsy is the gold standard for diagnosis, and the microscopic hallmark of PML is intranuclear basophilic or eosinophilic inclusions within the swollen nuclei of oligodendrocytes,
often at the periphery of lesions. Large, occasionally multinucleated astrocytes with prominent processes are another characteristic feature.

Pathogenesis of JCV Reactivation in Patients
Treated With MAB
Natalizumab
Natalizumab is a MAB against a4 integrin that prevents entry
of inflammatory cells into brain and other tissues that use a4
integrin very late atnigen - 4 (VLA-4) to bind with vascular
cell adhesion molecule (VCAM).24 This agent is mainly used
in multiple sclerosis (MS) to prevent acute relapse. The current estimate of the incidence of PML due to natalizumab use
is 1 in 1000 patients.25
The 3 main mechanisms by which natalizumab predisposes
patients to PML have been described. First, natalizumab has an
effect on the T cells which react against the active and dormant
JCV. The JCV-specific cytotoxic T lymphocytes are critical for
containing PML.26,27 These cells are most likely important not
only in the brain but also in other sites such as bone marrow and
spleen. It is anticipated that administration of natalizumab may
prevent the entry of these cytotoxic T cells into the brain tissue
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Table 1. Clinical and Pathological Features of PML.
Clinical features
 Hemiparesis, visual impairment, and altered mentation
 Headache, vertigo, and seizures
 Parkinson’s and aphasia
 Others depending on site of lesion
Radiological features
 Most likely subcortical lesion
 No ring enhancing
 CT scan demonstrates nonenhancing, subcortical hypodensities;
MRI scan shows altered signal from the subcortical lesions
Laboratory features of PML
 EEG shows focal slowing; CSF may show mild elevation of
protein or an increased cell count, viral antigen detection, viral
DNA detection, and demonstration of viral pathogens in the
lymphocytic cells
Pathological features
 The microscopic hallmark of the disease is intranuclear
basophilic or eosinophilic inclusions within the swollen nuclei of
oligodendrocytes, often at the periphery of lesions. Large,
occasionally multinucleated astrocytes with prominent
processes are another characteristic feature
Abbreviations: CSF, cerebrospinal fluid; CT, computed tomography; EEG, electroencephalogram; MRI, magnetic resonance imaging; PML, progressive multifocal leukoencephalopathy.

or other sites where JCV may be dormant, preventing JCV
suppression. Second, a4b1 VCAM mediates the homing and
retention of lymphocytes in the bone marrow and spleen.28
Blocking a4b1 integrin could result in a release of B cells from
the bone marrow and spleen,28 which are the common sites of
JCV latency. Coupled with diminished immunosurveillance for
JCV at these sites, this might increase the load of JCV in the
peripheral blood. Peripheral blood, supporting the premise that
B cells are mobilized by natalizumab and reports of increased
numbers of circulating lymphocytes29 following the administration of natalizumab. Another aspect of natalizumab therapy–induced PML is that all previous reports of PML after
natalizumab therapy involved patients who had undergone
concurrent treatment with either interferon bor other immunosuppressive agents suggesting that a suppressed immune
state is needed for the development of PML in patients treated
with natalizumab.24 According to Gorelik et al,30 the development of PML in patients on natalizumab is an interplay of 3
factors including duration of natalizumab treatment, the presence of anti-JCV antibodies, and concomitant use of other
immunosuppressants. The highest risk was observed in
patients treated with natalizumab for more than 24 months,
positive for anti-JCV antibodies, and concurrent use of immunosuppressive agents.
Since anti-JCV antibodies have been implicated as a factor
in the development of PML in patients on natalizumab, further
research is being done to develop an assay to help reduce PML
infections in these patients.30 Currently, an enzyme-linked
immunosorbent assay–based test that allows for the detection
of anti-JCV antibodies, indicating past infection, has been
developed and is offered for patient groups who have risk
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factors for PML such as treatment with natalizumab and rituximab and developing central nervous system (CNS) symptoms
or have a history of hematological malignancy.31,32 However, it
cannot distinguish between antibody against wild-type and
mutated viruses and is still being investigated at this time.
Other methods to detect JCV infection may not be sufficient
because of poor sensitivity (assays for JCV DNA in blood) or
only intermittent presence of virus in urine (assays for viral
DNA in urine). Urine viral DNA test is being tested to stratify
the risk for the development of PML in patients on natalizumab. Currently, there are no guidelines or recommendations
about testing for PML prior to treating with natalizumab in the
United States.

Rituximab
Rituximab is an agent that is Food and Drug Administration
(FDA) approved for the treatment of non-Hodgkin lymphoma
(NHL), chronic lymphocytic leukemia (CLL), rheumatoid
arthritis with methotrexate, granulomatosis with polyangiitis,
and microscopic polyangiitis in combination with glucocorticoids. The drug has also been used in non-FDA-approved treatment of immune thrombocytopenia, hemolytic anemias, other
autoimmune disorders, and Epstein–Barr virus reactivation.
Rituximab treatment has been associated with viral infectious
complications. In February 2006, 9 years after the drug received
its initial FDA approval, the labeling for rituximab was changed
to include information about patients with NHL who had developed serious viral infections after treatment with the drug. Infections included hepatitis B, cytomegalovirus, herpes simplex
virus, varicella zoster virus, West Nile virus, and JCV.11,33
The pathophysiology of rituximab-associated PML is unclear.
The mechanism underlying viral reactivation after rituximab
treatment is hypothesized to be more complex than simple
B-cell depletion.11,34 Stasi et al34 demonstrated changes in
T-lymphocyte cytokine profiles among patients with immune
thrombocytopenic purpura who responded to rituximab, suggesting that changes in T-lymphocyte activity after B-lymphocyte
depletion frequently occur. A role of B lymphocytes in JCV
immune responses is supported by JCV reactivation and development of PML in patients with congenital disorders of humoral
immunity.35-37 Experimental studies also suggested that hematopoietic progenitor cells might be a site of viral latency.38 Three
patients in a cohort study demonstrated JCV in paraffinembedded bone marrow biopsy samples obtained years before
rituximab administration. Hematopoietic progenitor cells mobilized into the peripheral blood during chemotherapy may have
been infected with latent JCV and may have facilitated hematogeneous spread of JCV into the CNS.39-41 As seen in natalizumab, PML associated with rituximab is also more frequently
seen in immunocompromised patients, which again suggests that
patients at risk are those who have greater immunosuppression.
Carson et al reviewed PML cases among patients treated with
rituximab included in the FDA database, the manufacturer, physicians, and literature reviews between 1997 and 2008. Overall,
52 patients with LPD, 2 patients with systemic lupus
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erythematosus, 1 patient with rheumatoid arthritis, 1 patient with
an idiopathic autoimmune pancytopenia, and 1 patient with
immune thrombocytopenia developed PML after treatment with
rituximab and other agents. Median time to death after PML
diagnosis was 2.0 months. The case fatality rate is 90%.
Due to the high case fatality rate, it is important for clinicians to keep in mind that patients on rituximab can develop
PML, and if relevant symptoms are present, discontinuation
of therapy and urgent workup are necessary to try to decrease
morbidity and mortality.41 A review of literature suggested 2
possible rituximab-associated PML syndromes. The first one
is associated with short interval between last rituximab dose
and PML diagnosis among patients with low CD4þ lymphocyte counts and occasionally low immunoglobulin G (IgG)
levels. The second syndrome is associated with longer interval between the last rituximab dose and PML diagnosis
among patients with higher CD4þ lymphocyte counts.42 At
this time, there are no recommendations to screen patients
for JCV prior to administration of rituximab and there is no
evidence that either type of rituximab-associated PML syndrome can be prevented with currently available therapeutic
measures.
The incidence of PML with natalizumab and rituximab in
HIV-negative patients is 1 in 1000 and 1 in 32 000, respectively. Incidence rates of PML in patients on rituximab and
natalizumab are similar to those in the HIV population, suggesting that better screening tools are needed to try to prevent
JCV reactivation in patients on these medications.

Other MAB and Risk of PML
Alemtuzumab
Alemtuzumab is a humanized MAB that targets the CD52
receptor on B, T, and natural killer lymphocytes and monocytes.43 It is FDA approved for uses in B-cell CLL. The drug
has been tested in acute graft-versus-host disease and autoimmune hemolytic anemias but is not approved for use in these
diseases. Clinical trials indicated that alemtuzumab has efficacy in the treatment of malignancies, such as NHL, B-cell
CLL, and T-cell prolymphocytic leukemia.44-46 It has also been
used in other diseases mediated by the immune system, such as
acute rejection of solid organ transplants,47 rheumatoid arthritis,48 and graft-versus-host disease.49 Because of its ability to
deplete T-cell populations, alemtuzumab has also been used as
a conditioning agent in solid organ transplantation and hematopoietic stem cell transplantation (HSCT).50-52 Martin et al
conducted a follow-up study on 27 patients on alemtuzumab
and described 1 case which developed PML.52 Another study
reported PML development in a few patients who were on
alemtuzumab.53,54 The mechanism responsible for PML is
due to depletion of cytotoxic T cells that kill or suppress the
latent JCV-infected cells. Rates of PML in patients with
alemtuzumab remain low, but clinicians should think about
this disease in patients on the medication with PML-like
symptoms.
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Efalizumab
Efalizumab is another immunomodulatory agent that acts by
binding to CD11a, the a subunit of leukocyte function
antigen-1, which is expressed on all leukocytes and
decreases cell surface expression of CD11a. Kothary et al54
described a study with 72 patients with psoriasis who were
on treatment with efalizumab and 13 of these developed
PML after an average treatment duration of 3 years. This
medication has also been tested in CLL with limited studies
at this time. The FDA-approved uses of efalizumab include
severe plaque psoriasis and antirejection therapy in certain
transplants. The drug was tested in patients with CLL but did
not receive an FDA approval for this use. The risk of PML in
patients with efalizumab is higher than most other medications and PML should also be considered in these patients
with appropriate symptoms.

Brentuximab Vedotin
Brentuximab vedotin (BV) is an anti-CD30 MAB–drug conjugate that was approved in 2011 for the treatment of patients
with anaplastic large-cell and relapsed classical Hodgkin lymphomas. It is also FDA approved to be as a consolidation therapy after autologous HSCT in patients with classical Hodgkin
lymphoma. It has been used in non-FDA-approved trials in
other CD30þ lymphomas and is being studied in the upfront
setting in classical Hodgkin lymphoma. CD30 is a membrane
glycoprotein and a member of the tumor necrosis factor (TNF)
receptor family, and signaling through CD30 can have pleiotropic effects, depending on the type and activation state of the
cell. The cytoplasmic CD30 domain interacts with multiple
members of the TNF receptor-associated factor family and is
capable of inducing apoptosis through the c-Jun N-terminal
kinase np38. It also mediates cell activation via nuclear factor
kappa B as well as effector functions via Fas-associated protein
with death domain.55-57
The ligand for CD30 is CD30L (CD153), a type 2 membrane protein with structural homology to TNF-a, TNF-b,
and CD40 ligand. Signaling mediated by CD30 promotes
cell proliferation and survival but can also induce antiproliferative responses and trigger cell death. Whether CD30
activation results in proliferation of cells or reduced viability depends on the cell type receiving the signal and the
environment in which the signal is delivered.58 Brentuximab
is a very important drug that has shown high remission rates
in Hodgkin lymphoma especially in people older than 60
years and has shown remission rates of greater than >50%.
Treatment with BV is currently a standard of care for
patients with relapsed or refractory systemic anaplastic large
cell lymphoma (ALCL) and for patients with relapsed or
refractory Hodgkin lymphoma after autologous stem cell
transplantation or at least 2 prior combination chemotherapy
regimens. This agent is now being tested in combination
with standard chemotherapy in both the first-line and
relapsed setting, and the results are very promising.59
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The BV is another MAB associated with the development of
PML. There are important clinical differences among patients
who developed PML after BV when compared with PML after
exposure to the MAB such as rituximab, efalizumab, and natalizumab.60 Time to the onset of symptoms and duration of BV
therapy before PML were much shorter in 5 patients reported
by Carson et al.60 The proposed mechanism resulting in PML
secondary to BV was a depletion of CD30-positive activated T
cells involved in JCV immune surveillance in the CNS. Clinicians should think about PML in patients on BV who present
with symptoms associated with the disease. Currently, no
screening recommendations have been made.
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Table 2. Incidence of PML in Different Populations.
Clinical Entity

Incidence (Post 1996)

General population
HIV
Natalizumab (HIV negative)
Rituximab (HIV negative)

1 per 200 000
1.3 per 1000
1 per 1000
1 per 32 000

Abbreviation: PML, progressive multifocal leukoencephalopathy.

obinutuzumab and ofatumumab which is likely why there are
increased risk of PML in patients with rituximab.65-68

Obinutuzumab

JAK 1 and 2 Inhibitors

Obinutuzumab is a recently approved MAB against CD20 that
has shown efficacy in B-cell malignancies and CLL. It is FDA
approved to be used with chlorambucil in CLL and with bendamustine in patients with relapsed follicular lymphoma after
rituximab use. The drug has also been tested in other lymphomas and autoimmune diseases. Obinutuzumab binds target
cells both directly and together with the other immune cells.61
B-cell lysis is caused by 2 main mechanisms upon binding to
CD20 including direct activation of intracellular death signaling pathways and/or activation of the complement cascade.62
Progressive multifocal leukoencephalopathy has not been
reported in patients on obinutuzumab.

Although not considered traditional MAB, Janus Kinase (JAK)
inhibitors have been reported to have PML reactivation. The
FDA-approved uses of JAK inhibitors currently are limited to
primary polycythemia vera and primary myelofibrosis. They
are being studied in other myeloproliferative disorders and
other hematological malignancies. The mechanism by which
these medications may cause reactivation of PML is due to the
fact that the JAK–signal transducer and activator of transcription (STAT) pathway have a very important role in host
defense and autoimmunity. The JAK mutations are associated
with primary immunodeficiency and complete STAT-1 deficiency, block interferon signaling, and can lead to lethal viral
and bacterial infection including PML. The literature shows
that the progression of the neurologic features of PML continues after withdrawing these drugs. This may be due to immune
reconstitution. More data are needed to truly know whether
PML reactivation is as common with JAK inhibitors as some
classical MABs targeting B cells.69

Oftumumab
Oftumumab is human IgG1-type anti-CD20 MAB.63 This
agent targets a different epitope of CD20 than rituximab, and
this may explain some of the difference between rituximab and
ofatumumab.64 This medication is FDA approved in combination with chlorambucil in untreated CLL and in refractory CLL
in patients who are refractory to fludarabine and alemtuzumab.
It is has been tested in other B-cell malignancies but has not
gained approval in other settings.
Progressive multifocal leukoencephalopathy was seen as
one of the complications of therapy with ofatumumab but is
not seen as commonly as in patients treated with natalizumab or
rituximab. Obinutuzumab and ofatumumab likely have lower
reported rates of PML than rituximab due to the paucity of
literature on complications of these 2 newer medications.
As more data are presented, one will be able to see whether
there is a difference in PML rates between different antiCD20 antibodies, and research will be needed to figure out
why this occurs. One reason may be because rituximab redistributes CD20 into detergent-resistant lipid rafts. This clustering promotes association with other complexes such as the
B-cell receptor, and binding to C1q, resulting in potent
complement-dependent cytotoxicity, and it binds to all available CD 20 sites. In contrast, the newer agents trigger potent
homotypic adhesion and lysosomal cell death and they bind to
only a half of all the available CD20 sites. The immunosuppression caused by rituximab is thought to be greater than of

Clinical Importance of PML
We have discussed the PML incidence with the use of rituximab and natalizumab in Table 2, and to highlight its importance, we have also mentioned the incidence of PML with HIV
in the same table. We see that the incidence of PML in patients
on natalizumab therapy is very comparable to that in HIVpositive population. From a clinical perspective, it is important
to know how to prevent PML reactivation. For this, we have to
understand the main risk factors for the development of PML
for patients on MAB. The presence of immunosuppression,
anti-JCV antibodies, and duration of immunosuppression are
the 3 most important reasons for PML reactivation. At this
time, a quantitative anti-JCV antibody index is currently being
investigated to determine its predictive value in detecting PML
and to show whether increasing titers could reflect an increasing risk.70 Initial interpretations of this serological test suggested that a negative status could be used to reassure
patients as the probability of developing PML is very low at
<1/10 000. Long-term studies like the AFFIRM and
STRATIFY-1 suggest that the serological status could change
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Table 3. Worldwide Guidelines for Monitoring Patients With Multiple Sclerosis Started on Natalizumab for Risk of PML.
Region

United States

United Kingdom73

Pretreatment No consensus Anti-JCV index at the beginning of
guidelines
treatment and then every 6 months
During
No consensus Serology and radiology
treatment
guidelines
Anti-JCV test every 6 months
<1.5—MRI every 6 months
>1.5—MRI every 3 months

Middle East and Africa74

Spain75

Anti-JCV antibody test at the beginning
and then every 6 months
Serology—Every 6 months Anti-JCV
antibody
Radiology—If JCV is positive, then MRI
every year from that point on

MRI 3 months before
treatment
Serology—None
Radiology—MRI based
on clinical suspicion

Abbreviations: JCV, John Cunningham polyomavirus; MRI, magnetic resonance imaging; PML, progressive multifocal leukoencephalopathy.

during MAB treatment and thus needed continuous monitoring
every 6 months.71
Leukocyte markers have also been evaluated as a new way
of determining risk of PML reactivation in patients on natalizumab. One of the proposed mechanism is downregulation of
CD49d and CD29 (subunit of VLA-4) expressions on both
CD4þ and CD8þ T cells has been shown in patients treated
with natalizumab72. This test is currently being evaluated and is
not ready for clinical use. Finally, a new test called the ELISPOT test for effector memory T cells (T-effector memory
cells) has been suggested as test for evaluating the risk of PML
development in patients on natalizumab.72 From a clinical perspective, PML should be considered in any patient who is on
long-term MAB such as natalizumab or rituximab for cancer or
other medical problems such as Crohn disease and MS and
testing should be done if clinical suspicion is high for PML.
Given the frequency of PML with natalizumab, different
societies around the world have guidelines in place to assist
clinicians during natalizumab therapy to monitor for PML.
Table 373-75 summarizes guidelines from various regions of the
world for monitoring patients with MS started on natalizumab
to assist physicians with possible early diagnosis and even
prevention of PML. To date, there are no guidelines for testing
patients for PML prior to the start of therapy for any other
MAB including rituximab.

Treatment of PML
Various antiviral drugs, including cidofovir, have been used
in addition to highly active antiretroviral therapy for the treatment of PML in patients with HIV but have not been effective.
Mefloquine, a drug approved for malaria therapy, has recently
shown to have an effect on the activity of JCV in a screening
bioassay when it is applied on a human glial cell line infected
with JCV.76 Mirtazapine, an inhibitor of 5-HT2a receptor,
which may be used by JCV for cell entry, has also been shown
to inhibit the infection of a human astroglial cell line. 77
Recently, an anecdotal report has shown the efficacy of mirtazapine in a patient with PML, although many experts doubt
that this therapeutic agent has substantial efficacy. At the
present time, if PML is discovered in a patient and due to
discontinuation of MAB, the medication is the most appropriate action. The use of other medications to try to aid in the
treatment of PML reactivation is currently experimental and

patients should be referred to tertiary care centers for care or
be placed on clinical trials.

Conclusion
Several distinct MABs employed in the treatment of various
lymphoproliferative and autoimmune disorders including natalizumab, rituximab, alemtuzumab, BV, efalizumab, ofatumumab, and obinutuzumab were associated with the development
of PML. The most important pathogenic mechanisms involved
in PML evolution secondary to the use of MAB include immunosuppression due to elimination/suppression of B cells, cytotoxic T cells, natural killer cells, or T helper cells.
All patients treated with the above MAB should be monitored for CNS symptoms, and if any new symptoms occur,
appropriate workup to rule out PML should be considered.
Further research will be necessary to better understand pathobiology of JCV in order to predict high-risk patients for the
development of PML prior to starting MAB therapy. Modern
laboratory serology and PCR-based tests might become a standard for JCV monitoring in near future but cannot currently be
recommended for use unless on a clinical trial.
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